2026
A+ VERIFIED
NU 578 Unit 4 Gastrointestinal Pharmacology Exam 2026/2027 75
Verified Questions & Answers Herzing University Nursing Instant
Download 98 Questions
Clinical | Rationale-Driven - Pass Guaranteed - A+ Graded
98 1 98
QUESTIONS SECTIONS RATIONALES
WHAT THIS COVERS
01 Gastrointestinal Pharmacology
02 Including acid-suppressive therapy
03 Antiemetics
04 Laxatives
05 Antidiarrheals
06 IBD biologics
ABOUT THIS ASSESSMENT
This exam assesses advanced pharmacologic knowledge of gastrointestinal agents, including acid-suppressive therapy, antiemetics,
laxatives, antidiarrheals, IBD biologics, IBS therapies, pancreatic enzymes, and related nursing management. It emphasizes
mechanisms, adverse effects, drug interactions, and evidence-based prescribing per current guidelines.
,EXAMINATION QUESTIONS
SECTION 1 - Gastrointestinal Pharmacology (Questions 1 to 98)
1. Which pancreatic enzyme product characteristic is essential for effective fat digestion in exocrine pancreatic
insufficiency?
A. Enteric coating to protect enzymes from gastric acid
B. High lipase content with immediate release
C. Combination with a proton pump inhibitor
D. Use of non-enteric coated tablets
Answer: A [Concept: Gastrointestinal Pharmacology]
Rationale: Enteric-coated pancreatic enzyme products (e.g., Creon, Zenpep) protect lipase from gastric acid inactivation and deliver
enzymes to the duodenum. Immediate-release or non-enteric formulations lose activity; PPIs are sometimes used adjunctively but are
not a product characteristic; high lipase alone without protection is ineffective.
2. Which 5-HT3 antagonist property most distinguishes palonosetron from ondansetron in chemotherapy-induced
nausea?
A. It has a longer half-life and higher receptor binding affinity
B. It is a partial dopamine D2 agonist
C. It is metabolized primarily by CYP2D6
D. It is ineffective for delayed emesis
Answer: A [Concept: Gastrointestinal Pharmacology]
Rationale: Palonosetron has a markedly longer half-life (~40 hours) and higher 5-HT3 receptor affinity than first-generation agents,
contributing to better control of delayed chemotherapy-induced nausea and vomiting. It is not a dopamine agonist, is not primarily
CYP2D6 metabolized, and is specifically indicated for delayed emesis.
3. Which pancreatic enzyme product characteristic is essential for effective steatorrhea control in exocrine pancreatic
insufficiency?
A. Enteric coating that dissolves at pH >5.5 with high lipase content
B. Immediate-release unprotected powder mixed in hot food
C. High amylase with minimal lipase activity
D. Delayed-release capsule taken on an empty stomach
Answer: A [Concept: Gastrointestinal Pharmacology]
Rationale: Effective PERT requires enteric-coated microspheres that resist gastric acid and release enzymes at duodenal pH, with
adequate lipase units per gram of fat ingested. Unprotected enzymes are inactivated by gastric acid, and amylase-rich, lipase-poor
products do not correct fat malabsorption. Enzymes must be taken with meals, not on an empty stomach.
4. Which PPI requires activation to a sulfenamide intermediate before irreversibly binding H+/K+-ATPase?
A. Omeprazole
B. Pantoprazole
C. Rabeprazole
D. Esomeprazole
Answer: A [Concept: Gastrointestinal Pharmacology]
Rationale: Omeprazole is a prodrug that undergoes acid-catalyzed conversion to a sulfenamide, which then covalently binds cysteine
residues on the proton pump. Pantoprazole, rabeprazole, and esomeprazole also form sulfenamide intermediates, but the question
specifically tests the prototype mechanism; omeprazole is the classic example taught. All PPIs share this mechanism, but omeprazole
is the reference agent for sulfenamide formation.
Page 2 | NU 578 Unit 4 Gastrointestinal Pharmacology Exam 2026/2027 75 Verified Questions & Answers Herzing University Nursing Instant
, 5. A patient on warfarin develops melena after starting a high-dose NSAID. Which co-prescribed GI agent most
increases bleeding risk?
A. Sucralfate
B. Misoprostol
C. Omeprazole
D. Famotidine
Answer: C [Concept: Gastrointestinal Pharmacology]
Rationale: Omeprazole inhibits CYP2C19, reducing warfarin metabolism and raising INR; combined with NSAID mucosal injury,
bleeding risk escalates. Sucralfate, misoprostol, and famotidine lack this CYP2C19-mediated warfarin interaction.
6. A patient with pancreatic exocrine insufficiency remains steatorrheic on pancrelipase. Which action is best?
A. Administer with a PPI to increase enzyme activity
B. Take capsules with meals and add a PPI or increase dose
C. Switch to a proton pump inhibitor alone
D. Crush enteric-coated capsules for faster release
Answer: B [Concept: Gastrointestinal Pharmacology]
Rationale: Pancrelipase should be taken with meals; if steatorrhea persists, adding a PPI to reduce acid inactivation or increasing the
dose is recommended. Crushing enteric-coated capsules destroys acid protection, and PPIs alone do not replace enzymes.
7. A patient with moderate ulcerative colitis on mesalamine develops worsening symptoms. Which factor most likely
explains treatment failure?
A. Rapid renal clearance of mesalamine
B. Nonadherence due to divided dosing or pill burden
C. Mesalamine resistance from beta-lactamase production
D. High-fat meals reducing mesalamine absorption
Answer: B [Concept: Gastrointestinal Pharmacology]
Rationale: Mesalamine efficacy in ulcerative colitis is highly adherence-dependent; complex dosing regimens (multiple daily doses or
high pill burden) are a leading cause of apparent treatment failure. Mesalamine is not renally cleared rapidly, not subject to
beta-lactamase resistance, and food does not significantly impair its colonic delivery.
8. Which agent is a 5-HT3 receptor antagonist used for irritable bowel syndrome with diarrhea?
A. Alosetron
B. Lubiprostone
C. Linaclotide
D. Rifaximin
Answer: A [Concept: Gastrointestinal Pharmacology]
Rationale: Alosetron is a 5-HT3 receptor antagonist approved for severe IBS-D in women, with restrictions due to ischemic colitis
risk. Lubiprostone (B) and linaclotide (C) are used for IBS-C; rifaximin (D) is an antibiotic used for IBS-D but not a 5-HT3
antagonist.
9. Which antiemetic is a neurokinin-1 receptor antagonist used for delayed chemotherapy-induced nausea?
A. Ondansetron
B. Aprepitant
C. Metoclopramide
D. Prochlorperazine
Answer: B [Concept: Gastrointestinal Pharmacology]
Rationale: Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P, effective for both acute and delayed
chemotherapy-induced nausea and vomiting. Ondansetron is a 5-HT3 antagonist primarily for acute CINV. Metoclopramide is a
dopamine antagonist and prokinetic. Prochlorperazine is a phenothiazine dopamine antagonist.
Page 3 | NU 578 Unit 4 Gastrointestinal Pharmacology Exam 2026/2027 75 Verified Questions & Answers Herzing University Nursing Instant
A+ VERIFIED
NU 578 Unit 4 Gastrointestinal Pharmacology Exam 2026/2027 75
Verified Questions & Answers Herzing University Nursing Instant
Download 98 Questions
Clinical | Rationale-Driven - Pass Guaranteed - A+ Graded
98 1 98
QUESTIONS SECTIONS RATIONALES
WHAT THIS COVERS
01 Gastrointestinal Pharmacology
02 Including acid-suppressive therapy
03 Antiemetics
04 Laxatives
05 Antidiarrheals
06 IBD biologics
ABOUT THIS ASSESSMENT
This exam assesses advanced pharmacologic knowledge of gastrointestinal agents, including acid-suppressive therapy, antiemetics,
laxatives, antidiarrheals, IBD biologics, IBS therapies, pancreatic enzymes, and related nursing management. It emphasizes
mechanisms, adverse effects, drug interactions, and evidence-based prescribing per current guidelines.
,EXAMINATION QUESTIONS
SECTION 1 - Gastrointestinal Pharmacology (Questions 1 to 98)
1. Which pancreatic enzyme product characteristic is essential for effective fat digestion in exocrine pancreatic
insufficiency?
A. Enteric coating to protect enzymes from gastric acid
B. High lipase content with immediate release
C. Combination with a proton pump inhibitor
D. Use of non-enteric coated tablets
Answer: A [Concept: Gastrointestinal Pharmacology]
Rationale: Enteric-coated pancreatic enzyme products (e.g., Creon, Zenpep) protect lipase from gastric acid inactivation and deliver
enzymes to the duodenum. Immediate-release or non-enteric formulations lose activity; PPIs are sometimes used adjunctively but are
not a product characteristic; high lipase alone without protection is ineffective.
2. Which 5-HT3 antagonist property most distinguishes palonosetron from ondansetron in chemotherapy-induced
nausea?
A. It has a longer half-life and higher receptor binding affinity
B. It is a partial dopamine D2 agonist
C. It is metabolized primarily by CYP2D6
D. It is ineffective for delayed emesis
Answer: A [Concept: Gastrointestinal Pharmacology]
Rationale: Palonosetron has a markedly longer half-life (~40 hours) and higher 5-HT3 receptor affinity than first-generation agents,
contributing to better control of delayed chemotherapy-induced nausea and vomiting. It is not a dopamine agonist, is not primarily
CYP2D6 metabolized, and is specifically indicated for delayed emesis.
3. Which pancreatic enzyme product characteristic is essential for effective steatorrhea control in exocrine pancreatic
insufficiency?
A. Enteric coating that dissolves at pH >5.5 with high lipase content
B. Immediate-release unprotected powder mixed in hot food
C. High amylase with minimal lipase activity
D. Delayed-release capsule taken on an empty stomach
Answer: A [Concept: Gastrointestinal Pharmacology]
Rationale: Effective PERT requires enteric-coated microspheres that resist gastric acid and release enzymes at duodenal pH, with
adequate lipase units per gram of fat ingested. Unprotected enzymes are inactivated by gastric acid, and amylase-rich, lipase-poor
products do not correct fat malabsorption. Enzymes must be taken with meals, not on an empty stomach.
4. Which PPI requires activation to a sulfenamide intermediate before irreversibly binding H+/K+-ATPase?
A. Omeprazole
B. Pantoprazole
C. Rabeprazole
D. Esomeprazole
Answer: A [Concept: Gastrointestinal Pharmacology]
Rationale: Omeprazole is a prodrug that undergoes acid-catalyzed conversion to a sulfenamide, which then covalently binds cysteine
residues on the proton pump. Pantoprazole, rabeprazole, and esomeprazole also form sulfenamide intermediates, but the question
specifically tests the prototype mechanism; omeprazole is the classic example taught. All PPIs share this mechanism, but omeprazole
is the reference agent for sulfenamide formation.
Page 2 | NU 578 Unit 4 Gastrointestinal Pharmacology Exam 2026/2027 75 Verified Questions & Answers Herzing University Nursing Instant
, 5. A patient on warfarin develops melena after starting a high-dose NSAID. Which co-prescribed GI agent most
increases bleeding risk?
A. Sucralfate
B. Misoprostol
C. Omeprazole
D. Famotidine
Answer: C [Concept: Gastrointestinal Pharmacology]
Rationale: Omeprazole inhibits CYP2C19, reducing warfarin metabolism and raising INR; combined with NSAID mucosal injury,
bleeding risk escalates. Sucralfate, misoprostol, and famotidine lack this CYP2C19-mediated warfarin interaction.
6. A patient with pancreatic exocrine insufficiency remains steatorrheic on pancrelipase. Which action is best?
A. Administer with a PPI to increase enzyme activity
B. Take capsules with meals and add a PPI or increase dose
C. Switch to a proton pump inhibitor alone
D. Crush enteric-coated capsules for faster release
Answer: B [Concept: Gastrointestinal Pharmacology]
Rationale: Pancrelipase should be taken with meals; if steatorrhea persists, adding a PPI to reduce acid inactivation or increasing the
dose is recommended. Crushing enteric-coated capsules destroys acid protection, and PPIs alone do not replace enzymes.
7. A patient with moderate ulcerative colitis on mesalamine develops worsening symptoms. Which factor most likely
explains treatment failure?
A. Rapid renal clearance of mesalamine
B. Nonadherence due to divided dosing or pill burden
C. Mesalamine resistance from beta-lactamase production
D. High-fat meals reducing mesalamine absorption
Answer: B [Concept: Gastrointestinal Pharmacology]
Rationale: Mesalamine efficacy in ulcerative colitis is highly adherence-dependent; complex dosing regimens (multiple daily doses or
high pill burden) are a leading cause of apparent treatment failure. Mesalamine is not renally cleared rapidly, not subject to
beta-lactamase resistance, and food does not significantly impair its colonic delivery.
8. Which agent is a 5-HT3 receptor antagonist used for irritable bowel syndrome with diarrhea?
A. Alosetron
B. Lubiprostone
C. Linaclotide
D. Rifaximin
Answer: A [Concept: Gastrointestinal Pharmacology]
Rationale: Alosetron is a 5-HT3 receptor antagonist approved for severe IBS-D in women, with restrictions due to ischemic colitis
risk. Lubiprostone (B) and linaclotide (C) are used for IBS-C; rifaximin (D) is an antibiotic used for IBS-D but not a 5-HT3
antagonist.
9. Which antiemetic is a neurokinin-1 receptor antagonist used for delayed chemotherapy-induced nausea?
A. Ondansetron
B. Aprepitant
C. Metoclopramide
D. Prochlorperazine
Answer: B [Concept: Gastrointestinal Pharmacology]
Rationale: Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P, effective for both acute and delayed
chemotherapy-induced nausea and vomiting. Ondansetron is a 5-HT3 antagonist primarily for acute CINV. Metoclopramide is a
dopamine antagonist and prokinetic. Prochlorperazine is a phenothiazine dopamine antagonist.
Page 3 | NU 578 Unit 4 Gastrointestinal Pharmacology Exam 2026/2027 75 Verified Questions & Answers Herzing University Nursing Instant
